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weBACKGROUND High-sensitivity assays can quantify cardiac troponins I and T (hs-cTnI, hs-cTnT) in individuals with no
clinically manifest myocardial injury.
OBJECTIVES The goal of this study was to assess associations of cardiac troponin concentration with cardiovascular
disease (CVD) outcomes in primary prevention studies.
METHODS A search was conducted of PubMed, Web of Science, and EMBASE for prospective studies published
up to September 2016, reporting on associations of cardiac troponin concentration with ﬁrst-ever CVD outcomes
(i.e., coronary heart disease [CHD], stroke, or the combination of both). Study-speciﬁc estimates, adjusted for
conventional risk factors, were extracted by 2 independent reviewers, supplemented with de novo data from
PROSPER (Pravastatin in Elderly Individuals at Risk of Vascular Disease Study), then pooled by using random
effects meta-analysis.
RESULTS A total of 28 relevant studies were identiﬁed involving 154,052 participants. Cardiac troponin was detectable
in 80.0% (hs-cTnI: 82.6%; hs-cTnT: 69.7%). In PROSPER, positive associations of log-linear shape were observed
between hs-cTnT and CVD outcomes. In the meta-analysis, the relative risks comparing the top versus the bottom
troponin third were 1.43 (95% conﬁdence interval [CI]: 1.31 to 1.56) for CVD (11,763 events), 1.67 (95% CI: 1.50 to 1.86)
for fatal CVD (7,775 events), 1.59 (95% CI: 1.38 to 1.83) for CHD (7,061 events), and 1.35 (95% CI: 1.23 to 1.48) for stroke
(2,526 events). For fatal CVD, associations were stronger in North American studies (p ¼ 0.010) and those measuring
hs-cTnT rather than hs-cTnI (p ¼ 0.027).
CONCLUSIONS In the general population, high cardiac troponin concentration within the normal range is
associated with increased CVD risk. This association is independent of conventional risk factors, strongest
for fatal CVD, and applies to both CHD and stroke. (J Am Coll Cardiol 2017;70:558–68) © 2017 The Authors.
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AB BR E V I A T I O N S
AND ACRONYM S
CHD = coronary heart disease
CI = conﬁdence interval
CRP = C-reactive protein
CVD = cardiovascular disease
eGFR = estimated glomerular
ﬁltration rate
HDL-C = high-density
lipoprotein cholesterol
HR = hazard ratio
hs-cTnI = high-sensitivity
cardiac troponin I
hs-cTnT = high-sensitivity
cardiac troponin T
MI = myocardial infarction
NRI = net reclassiﬁcation index
NT-proBNP = N-terminal pro–
B-type natriuretic peptide
RR = relative risk
J A C C V O L . 7 0 , N O . 5 , 2 0 1 7 Willeit et al.
A U G U S T 1 , 2 0 1 7 : 5 5 8 – 6 8 Cardiac Troponins and Cardiovascular Outcomes
559C ardiac troponins are structural proteins in thecontractile apparatus of cardiac myocytesthat are released into the circulation after car-
diac myocyte cell death (1). Since the introduction of
the ﬁrst troponin assays in the early 1990s, measure-
ment of circulating cardiac troponin concentration
has become a cornerstone in the diagnosis and acute
management of myocardial infarction (MI) (2). Devel-
opment of high-sensitivity assays allowed the detec-
tion of cardiac troponin I and T (hs-cTnI and hs-cTnT,
respectively) at lower concentrations, which enabled
earlier identiﬁcation of myocardial injury and
increased diagnostic accuracy in patients with sus-
pected MI (3).
At the same time, these methodological advances
have led to a fundamental change in the clinical
interpretation of cardiac troponin assay results.
Although patients traditionally have been classiﬁed
as being “troponin-positive” or “troponin-negative”
in the context of the diagnosis of acute MI, new-
generation assays allow a continuous interpretation
of ﬁndings (i.e., higher vs. lower concentration).
Furthermore, high-sensitivity assays can detect
circulating cardiac troponin in individuals with no
clinically manifest myocardial damage or previous
cardiovascular disease (CVD).SEE PAGE 569Recent studies in subjects recruited from the gen-
eral population have suggested that elevations in
circulating cardiac troponin are associated with a
higher risk of a ﬁrst-ever CVD event (4–30). The
largest such study, from the BiomarCaRE (Biomarkers
for Cardiovascular Risk Assessment in Europe)
consortium, reported a hazard ratio (HR) for CVD of
1.92 (95% conﬁdence interval [CI]: 1.76 to 2.10)
comparing the highest versus the lowest quintile of
hs-cTnI concentration (11). Although these studies
have yielded promising ﬁndings, their interpretation
and comparison have been hampered by use of
different scales and inconsistent adjustment of effect
estimates. To clarify associations of cardiac troponins
with incident CVD, the present study collated effect
estimates from published studies conducted in
populations free of previous CVD, supplementedAgency FFG: “Research Center of Excellence in Vascular Ageing—Tyrol, VAS
BMWFW, Wirtschaftsagentur Wien, and Standortagentur Tirol. Dr. Evans
Research Excellence. Drs. Welsh and Sattar’s cardiac biomarker work is sup
Scientist Ofﬁce of the Scottish Government (ASM/14/1). All other authors have
the contents of this paper to disclose. Drs. Willeit, Welsh, and Evans contribu
Angelantonio and Sattar contributed equally to this work as joint senior aut
Manuscript received April 6, 2017; revised manuscript received May 30, 201them with de novo data, and combined them
in a meta-analysis.
METHODS
We systematically searched the electronic
databases PubMed, Web of Science, and
EMBASE for prospective studies published up
to September 2016 that reported on associa-
tions of cardiac troponin concentration with
incident CVD outcomes. The search strategy
is detailed in Online Table 1. Studies were
eligible for inclusion if they: 1) had measured
hs-cTnI and/or hs-cTnT with a high-
sensitivity assay; 2) had recruited partici-
pants not based on having a history of CVD at
baseline; and 3) had recorded CVD outcomes
over more than 1 year of follow-up. We
further obtained unpublished tabular data
from the Bruneck Study through direct cor-
respondence with study investigators (31).
Using standardized data extraction protocols, 2
independent reviewers (P.W. and J.D.W.E.) extracted,
by consensus, information on geographical location,
baseline survey dates, study design, exclusion of
participants with pre-existing CVD, mean age at
baseline, proportion of male subjects, proportion of
white participants, sample type, cardiac troponin
assay manufacturer, assay detection limit, proportion
of participants with detectable cardiac troponin, and
number of participants in the study. In relation to
incident outcomes, the reviewers extracted data on
duration of follow-up, the speciﬁc composition of
reported endpoints, the number of outcomes accrued,
effect sizes, and the degree of statistical adjustment
of any reported association. The degree of adjustment
was classiﬁed as “o” when relative risks (RRs) were
adjusted for age and sex only, “þ” when RRs were
adjusted for conventional risk factors (age, sex,
smoking, diabetes, blood pressure, and total and
high-density lipoprotein cholesterol [HDL-C]); “þþ”
when RRs were also adjusted for C-reactive protein
(CRP) or serum creatinine; and “þþþ” after further
adjustment for B-type natriuretic peptides. If multi-
ple publications on the same study were available,Cage” (K-Project No. 843536) funded by the BMVIT,
was supported by the BHF Cambridge Centre for
ported by a stratiﬁed medicine grant from the Chief
reported that they have no relationships relevant to
ted equally to this work as joint ﬁrst authors. Drs. Di
hors.
7, accepted May 30, 2017.
FIGURE 1 PROSPER: hs-cTnT Associations With CVD Outcomes
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After multivariable adjustment, models were stratiﬁed according to treatment arm; the
group with undetectable high-sensitivity cardiac troponin T (hs-cTnT) values was used as
the reference group. The median hs-cTnT concentrations (ranges) in quartiles of
detectable hs-cTnT were 4 ng/l (3 to 4), 6 ng/l (5 to 7), 9 ng/l (8 to 11), and 16 ng/l
(12 to 1,840). Sizes of data markers are proportional to the inverse of the variance
of the hazard ratios. CHD ¼ coronary heart disease; CI ¼ conﬁdence interval;
CVD ¼ cardiovascular disease. PROSPER ¼ Pravastatin in Elderly Individuals at Risk of
Vascular Disease Study.
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560the most up-to-date or comprehensive information
was used. Methods and results are reported in
accordance with the Preferred Reporting Items for
Systematic Review and Meta-Analysis Protocols
guidelines (32).
THE PROSPER STUDY. PROSPER (Pravastatin in
Elderly Individuals at Risk of Vascular Disease
Study) was a randomized, double-blind, placebo-
controlled pravastatin trial in individuals with pre-
existing CVD or risk factors thereof (i.e., smoking,
hypertension, diabetes) (33,34). The present analysis
involved 4,402 participants with no previous CVD
and with complete information on hs-cTnT and
covariates, recruited at study centers in Scotland,
Ireland, and the Netherlands (Online Figure 1).
Measurement of hs-cTnT used plasma samples
obtained 6 months after randomization using ahigh-sensitivity electrochemiluminescence immu-
noassay. The occurrence of incident outcomes was
adjudicated by the PROSPER Endpoints Committee
during the in-trial phase (mean duration: 3.2 years)
and ascertained with routine health data thereafter.
The institutional ethics review boards of all centers
approved the protocol, and all participants gave
written informed consent. The protocol adhered to
the principles of the Declaration of Helsinki. Further
details are provided in the Online Appendix.
STATISTICAL ANALYSIS. The statistical analysis was
conducted according to a pre-deﬁned statistical
analysis plan. The combined CVD endpoint was
deﬁned as fatal coronary heart disease (CHD),
nonfatal MI, and fatal plus nonfatal stroke (ischemic,
hemorrhagic, or unclassiﬁed). In PROSPER, we
assessed cross-sectional associations between hs-
cTnT and other characteristics by using linear and
logistic regression models (for continuous and cate-
gorical data, respectively), adjusted for age, sex,
center, and treatment arm. HRs were calculated for
CVD outcomes stratiﬁed according to treatment arm
and were progressively adjusted for age, sex, and
center (model 1), plus smoking, history of diabetes
mellitus, history of hypertension, systolic blood
pressure, total cholesterol, HDL-C, and body mass
index (model 2), plus CRP, estimated glomerular
ﬁltration rate (eGFR), and N-terminal pro–B-type
natriuretic peptide (NT-proBNP) (model 3).
To characterize shapes of associations with CVD
outcomes, HRs were calculated across quartiles of
detectable hs-cTnT concentration by using partici-
pants with undetectable hs-cTnT as the reference
group, and HRs were plotted against the median hs-
cTnT concentration within each category. For the
outcomes of CVD and fatal CVD, effect modiﬁcation
was explored across clinically relevant subgroups
with formal tests of interaction. We also tested
whether assessment of hs-cTnT, in addition to age,
sex, smoking status, history of diabetes mellitus,
systolic blood pressure, and levels of total cholesterol
and HDL-C, could improve the prediction of 10-year
CVD risk. C-index changes as well as categorical and
continuous net reclassiﬁcation indexes (NRIs) were
calculated by using previously published methods
(35,36). Categorical NRIs were calculated across 10-
year predicted risk categories of <15%, 15% to <25%,
and $25%, chosen to reﬂect the elevated risk in the
study population; 95% CIs were estimated for these
prediction metrics by using bootstrap resampling
with 999 repetitions.
Study-speciﬁc risk estimates were pooled by using
random effects meta-analyses. Odds ratios and HRs
were assumed to approximate the same underlying
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561measure of RR. When studies reported RRs of various
levels of adjustment, the most adjusted estimate was
used. To enable a consistent approach to analysis,
RRs and 95% CIs in each study were standardized to a
common scale (i.e., to reﬂect a comparison of the top
third vs. the bottom third of the population’s cardiac
troponin distribution, using methods previously
described) (37). Consistency of ﬁndings across studies
was assessed with standard chi-square tests and the I2
statistic (38). Subgroup analyses were conducted by
using meta-regression across pre-speciﬁed study-
level characteristics (39). Evidence of publication bias
was assessed by using funnel plots and Egger’s
asymmetry test (40). Statistical tests were 2-sided and
used a signiﬁcance level of p < 0.05 for principal
analyses and p < 0.01 for subgroup analyses.
RESULTS
In PROSPER, hs-cTnT was detectable in 3,853 (87.5%)
of 4,402 participants. The median concentration of
hs-cTnT was 7 ng/l (interquartile range: 4 to 11 ng/l),
and 85% of hs-cTnT values were within the normal
range of #14 ng/l. Concentration of hs-cTnT corre-
lated positively with age, male sex, body mass index,
blood pressure, NT-proBNP, CRP, history of diabetes
mellitus, and history of hypertension (Online
Table 2). Concentration of hs-cTnT was lower in cur-
rent smokers and correlated inversely with renal
function assessed by eGFR. There was no difference
in hs-cTnT according to trial arm.
In the overall cohort, 694 fatal CVD events were
recorded over a follow-up duration of up to 11.3 years
(mean: 8.2 years). At the Scottish center, 519 fatal and
nonfatal CVD events, 405 CHD events, and 269 stroke
events were recorded. After adjusting for age, sex,
smoking, history of diabetes mellitus, history of hy-
pertension, systolic blood pressure, total cholesterol,
HDL-C, and body mass index, the shapes of associa-
tions between baseline hs-cTnT concentration and
CVD outcomes were approximately log linear
(Figure 1). The adjusted HRs for a comparison of the top
third versus the bottom third of the hs-cTnT concen-
tration were 1.55 (95% CI: 1.23 to 1.96) for CVD, 2.16
(95% CI: 1.74 to 2.67) for fatal CVD, 1.85 (95% CI: 1.42 to
2.42) for CHD, and 1.21 (95% CI: 0.88 to 1.67) for stroke.
There was some attenuation of estimates after further
adjustment for CRP, eGFR, and NT-proBNP (Online
Table 3). There was no evidence for effect modiﬁca-
tion by a range of participant characteristics, including
age, sex, diabetes, eGFR, and NT-proBNP, but there
was evidence for a somewhat stronger association in
never- or ex-smokers compared with current smokers
(Online Figure 2).LITERATURE-BASED META-ANALYSIS. We screened
4,645 records and identiﬁed 28 eligible prospective
studies (4–30) reporting on a total of 154,052 partici-
pants (Table 1, Online Figure 3). Eighteen studies were
based in Europe, 7 in North America, 1 in Asia, and 2
were multinational. The mean age was 56.1 years,
52.8% of participants were male, and 88.6% were
white. Seventeen studies hadmeasured hs-cTnI and 11
had measured hs-cTnT. The proportion of participants
with detectable cardiac troponin concentrations was
80.0% overall (82.6% in hs-cTnI studies and 69.7% in
hs-cTnT studies). Multivariable regression analyses
weighting studies according to their size identiﬁed
that the proportion of participants with detectable
troponin was higher in hs-cTnI studies (p ¼ 0.007) and
in older study populations (8.3% per decade higher
mean age; p ¼ 0.009) but was unrelated to sex distri-
butions (p ¼ 0.155). Figure 2 displays the proportion of
troponin detection according to study, assay type, and
mean age of the study population.
The combined RR in the top third versus the bottom
third of cardiac troponin concentration was 1.43 for
CVD, 1.67 for fatal CVD, 1.59 for CHD, and 1.35 for stroke
(Figure 3). Forest plots for each outcome are shown in
Online Figures 4 to 7. The level of between-study
heterogeneity was low for stroke (I2 ¼ 0%; p ¼ 0.764)
and high for other outcomes (I2 >75%; all p < 0.001).
Magnitudes of associations with CVD and fatal CVD
were largely similar across studies grouped according
to geographical regions, in studies nested versus those
not nested in clinical trials (Online Figure 8), and for
different mean ages of study participants, proportions
of male participants, and numbers of recorded events
(Online Figure 9). Associations for fatal CVD were
somewhat stronger in studies based in North America
(p¼0.010) (Online Figure 8) and studiesmeasuring hs-
cTnT rather than hs-cTnI (p ¼ 0.027) (Online Figure 8).
Associations with CVD were stronger in studies with a
higher proportion of nonwhite participants (p¼0.004)
(Online Figure 9). There was evidence for publication
bias in reporting associations with fatal CVD
(pEgger ¼ 0.027) but not for the other outcomes
assessed (Online Figure 10).
The addition of hs-cTnT concentration to a predic-
tion model containing information on conventional
risk factors improved the prediction of fatal CVD
(Online Table 4). It improved the C-index by 0.028
(95% CI: 0.007 to 0.050; p ¼ 0.018), the categorical NRI
by 0.123 (95% CI: 0.074 to 0.153; p < 0.001), and the
continuous NRI by 0.357 (95% CI: 0.277 to 0.436;
p < 0.001). In contrast, for the overall CVD outcome,
smaller improvements in the continuous NRI of 0.152
(95% CI: 0.052 to 0.253; p ¼ 0.003) were observed,
whereas no improvements were observed in the
TABLE 1 Characteristics of Prospective Studies
Study (Ref. #) Location
Baseline Survey
Date (Range) Study Design
Mean
Follow-Up, Yrs
Mean
Age, Yrs Male, % White, %
ADVANCE (4) United States 2001–2004 PC 11.3* 62.1 50.8 62.1
AGES-Reykjavik (5) Iceland 2002–2006 PC 8.2* 77.0 42.5 100.0
ARIC (6–9) United States 1996–1998 PC 12.1 62.7 43.8 78.3
BRHS (10) United Kingdom 1998–2000 PC 13.0* 68.6 100.0 99.0
BRIANZA (11) Italy 1986–1993 PC 15.0* 46.7* 49.3 NR
BRUN Italy 2000 PC 10.0† 65.4 46.1 100.0
CAERPHILLY (11) United Kingdom 1989–1993 PC 22.2† 62.4* 100.0 100.0
CHS (12,13) United States 1989–1993 PC 11.8* 72.7 40.5 83.8
CIRCS (14) Japan 2001–2011 NCC 2.0* 38.0–86.0‡ 68.0 0.0
DAN-MONICA (11) Denmark 1982–1992 PC 29.0† 50.0* 50.6 NR
DHS (15) United States 2000–2002 PC 6.4* 44.8 44.1 29.4
FHS (16) United States 1995–1998 PC 11.3 59.0 46.9 100.0
FINRISK97 (17) Finland 1997 PC 14.0† 47.8* 49.7 100.0
HUNT2 (18,19) Norway 1995–1997 PC 13.9 50.0* 45.6 97.0
JUPITER (20) Multinational 2003–2006 PC§ 2.0* 66.0* 67.7 81.8
KORA (11,21) Germany 1994–2001 PC/CCohk 14.5† 50.5* 49.7 NR
MFS (10) United Kingdom 1996 PC 17.3* 45.1 44.5 100.0
MHS (22) United States 1990–1997 NCC 15.0† 67.0 62.1 97.0
MOLI-SANI (11) Italy 2005–2010 PC 4.2* 54.6* 48.1 NR
PIVUS (23,24) Sweden 2001 PC 10.0* 70.0 50.0 100.0
PREVEND (25) Netherlands 1997 PC 12.0† 49.3 49.8 94.9
PRIME-BEL (11) United Kingdom 1990–1993 PC 12.0† 54.7* 100.0 NR
PROSPER Multinational 1997–1999 PC§ 8.2 75.3 44.8 100.0
SHHEC (11,29) United Kingdom 1984–1995 PC 20.0 48.9 50.4 NR
SHIP (11) Germany 1997–2001 PC 11.0† 50.0* 48.7 NR
ULSAM (26) Sweden 1991–1995 PC 10.0* 71.0 100.0 100.0
WHS (27) United States 1992–1995 PC/CCoh§¶ 12.3* 56.5* 0.0 90.8
WOSCOPS (28) United Kingdom 1989–1991 PC§ 15.0† 55.1 100.0 NR
Total 1982–2011 11.9 56.1 52.8 88.6
Values are ranges, weighted means, or sums, unless otherwise indicated. *Median. †Maximum. ‡Range. §Prospective study was nested in a trial. kThe KORA study reported on the association with CHD events
in a case-cohort dataset (2,748 participants, maximum follow-up of 16 years, hs-cTnI measured with the Erenna assay). ¶The WHS investigated results separately for participants with and without diabetes
(using a prospective study and case-cohort design, respectively).
ADVANCE ¼ Atherosclerotic Disease, Vascular Function and Genetic Epidemiology Study; AGES-Reykjavik ¼ Age, Gene/Environment Susceptibility-Reykjavik Study; ARIC ¼ Atherosclerosis Risk in Com-
munities Study; BRHS ¼ British Regional Heart Study; BRIANZA ¼ MONICA Brianza Study; BRUN ¼ Bruneck Study; CAERPHILLY ¼ Caerphilly Prospective Study; CCoh ¼ case-cohort study; CHD ¼ coronary
heart disease; CHS ¼ Cardiovascular Health Study; CIRCS ¼ Circulatory Risk in Communities Study; CVD ¼ cardiovascular disease; DAN-MONICA ¼ Danish MONICA Study; DHS ¼ Dallas Heart Study;
FHS ¼ Framingham Heart Study; FINRISK97 ¼ FINRISK 1997 Survey; hs-cTnI ¼ high-sensitivity cardiac troponin I; hs-cTnT ¼ high-sensitivity cardiac troponin T; HUNT2 ¼ Nord-Trondelag Health Study 2;
JUPITER ¼ Justiﬁcation for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin Trial; KORA ¼ Kooperative Gesundheitsforschung in der Region Augsburg; MFS ¼ MIDSPAN Family
Study; MHS ¼ Minnesota Heart Study; MOLI-SANI ¼ Moli-Sani Project; NCC ¼ nested case-control study; NR ¼ not reported; PC ¼ prospective cohort study; PIVUS ¼ Prospective Investigation of the
Vasculature in Uppsala Seniors Study; PREVEND ¼ Prevention of Renal and Vascular End Stage Disease Study; PRIME-BEL ¼ Prospective Epidemiological Study of Myocardial Infarction from Belfast;
PROSPER ¼ Pravastatin in Elderly Individuals at Risk of Vascular Disease Study; SHHEC ¼ Scottish Heart Health Study and Scottish MONICA; SHIP ¼ Study of Health in Pomerania; ULSAM ¼ Uppsala
Longitudinal Study of Adult Men; WHS ¼ Women’s Health Study; WOSCOPS ¼ West of Scotland Coronary Prevention Study.
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Detailed reclassiﬁcation data are provided in Online
Table 5.
DISCUSSION
In the present report that combined de novo data
from the PROSPER study with a comprehensive
literature-based meta-analysis, we reliably quantiﬁed
associations of baseline cardiac troponin measure-
ments with ﬁrst-ever CVD outcomes (Central
Illustration). We further determined the added pre-
dictive value of such measurements in the primary
prevention of CVD.ASSOCIATIONS WITH CVD OUTCOMES. Overall, the
present systematic review and meta-analysis
involved data from 28 long-term prospective
studies with a total of 154,052 participants without
previous CVD. All included studies measured cardiac
troponins hs-cTnT or hs-cTnI with high-sensitivity
assays and reported detectable levels in 80% of
people, on average. Pooled estimates from the meta-
analysis suggest that individuals with cardiac
troponin values in the top third of the population
distribution are at 43% increased risk of any CVD,
59% increased risk of CHD, and 67% increased risk of
fatal CVD outcomes. A smaller but signiﬁcant in-
crease in stroke risk (35%) was noted. It is likely that
TABLE 1 Continued
Type of Troponin
(Assay) Sample Type Detection Limit, ng/l
Detectable
Troponin, % Participants, n
No. of Events
CVD CHD Stroke Fatal CVD
hs-cTnI (Abbott) Serum 1.2 100 1,135 – 164 – –
hs-cTnI (Abbott) Serum 1.2 100 5,691 957 716 – –
hs-cTnT (Roche) Plasma 3.0 68 10,350 610 527 507 358
hs-cTnT (Roche) Plasma 3.0 99 2,715 475 – – –
hs-cTnI (Abbott) Serum 1.9 75 4,932 393 – – 167
hs-cTnT (Roche) Serum 12.0 95 642 74 33 37 49
hs-cTnI (Abbott) Serum 1.9 75 2,171 583 – – 470
hs-cTnT (Roche) Serum 3.0 66 4,221 – – NR 1,103
hs-cTnT (Roche) Serum 3.0 NR 360 – 120 – –
hs-cTnI (Abbott) Serum 1.9 75 7,582 1,326 - – 1,002
hs-cTnT (Roche) Serum 3.0 27 3,459 – – – 59
hs-cTnI (Erenna) Plasma 0.2 81 3,265 334 173 – –
hs-cTnI (Erenna) Serum 1.0 94 7,899 770 363 299 –
hs-cTnI (Abbott) Serum 1.2 96 9,712 – 292 – 708
hs-cTnI (Abbott) Plasma 1.9 92 12,956 304 224 70 46
hs-cTnI (Abbott) Serum 1.9 75 8,913 525 803 – 331
hs-cTnT (Roche) Plasma 3.0 95 1,721 135 – – –
hs-cTnI (Erenna) Serum NR 100 464 – – – 211
hs-cTnI (Abbott) Serum 1.9 75 24,325 473 – – 151
hs-cTnI (Abbott) Plasma 1.5 96 1,004 163 – – 37
hs-cTnT (Roche) Plasma 3.0 NR 8,121 – 583 – –
hs-cTnI (Abbott) Serum 1.9 75 2,745 505 – – 149
hs-cTnT (Roche) Plasma 3.0 88 4,402 519 405 269 694
hs-cTnI (Abbott) Serum 1.9 75 16,000 2,953 1,980 797 1,786
hs-cTnI (Abbott) Serum 1.9 75 3,871 – – – 38
hs-cTnT (Roche) Plasma 3.0 93 561 148 86 62 46
hs-cTnT (Roche) Plasma 3.0 35 1,517 516 176 272 119
hs-cTnI (Abbott) Plasma 1.2 99.8 3,318 – 413 213 251
80.0 154,052 11,763 7,061 2,526 7,775
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563this association was driven by cardiac and heart
rhythm abnormalities causing ischemic stroke,
including paroxysmal atrial ﬁbrillation (41). An
analysis of the Atherosclerosis Risk in Communities
Study according to stroke subtype revealed prefer-
ential associations of hs-cTnT with cardioembolic
stroke (8). Furthermore, Wrigley et al. (42) recently
reported that, in patients with acute ischemic stroke,
an elevated troponin concentration was associated
with structural cardiac disease detected by using
echocardiography.
Our ﬁndings in the meta-analysis were further
substantiated by analyses of PROSPER study data,
showing that subjects with higher bloodconcentrations of hs-cTnT were at higher risk of
developing fatal and nonfatal CVD and CHD. Associ-
ations were independent of conventional CVD risk
factors and persisted even after additional adjust-
ment for NT-proBNP, eGFR, and CRP. We could also
conﬁrm a previous suggestion from the BiomarCaRE
consortium (11) that the risk of these diseases
increased approximately log linearly with higher
cardiac troponin concentration, with no evidence for
a threshold effect at a certain level. It is striking that
we observed signiﬁcant positive associations with
CVD outcomes even though 85% of the study popu-
lation had hs-cTnT values within the normal range
(#14 ng/l) at baseline.
FIGURE 2 Detectable Cardiac Troponin Concentrations
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The percentage of participants with detectable cardiac troponin concentrations was categorized by mean age and assay type per included
study. The red line and gray area represent the line of best ﬁt and 95% conﬁdence interval, respectively, with individual studies being
weighted according to their number of participants. ADVANCE ¼ Atherosclerotic Disease, Vascular Function and Genetic Epidemiology Study;
AGES-Reykjavik ¼ Age, Gene/Environment Susceptibility-Reykjavik Study; ARIC ¼ Atherosclerosis Risk in Communities Study;
BiomarCaRE ¼ Biomarkers for Cardiovascular Risk Assessment in Europe; BRHS ¼ British Regional Heart Study; BRUN ¼ Bruneck Study;
CHS ¼ Cardiovascular Health Study; DHS ¼ Dallas Heart Study; FHS ¼ Framingham Heart Study; FINRISK97 ¼ FINRISK 1997 Survey; hs-
cTnT ¼ high-sensitivity cardiac troponin T; HUNT2 ¼ Nord-Trondelag Health Study 2; JUPITER ¼ Justiﬁcation for the Use of Statins in
Prevention: An Intervention Trial Evaluating Rosuvastatin Trial; MFS ¼ MIDSPAN Family Study; MHS ¼ Minnesota Heart Study;
PIVUS ¼ Prospective Investigation of the Vaculature in Uppsala Seniors Study; PROSPER ¼ Pravastatin in Elderly Individuals at Risk of
Vascular Disease Study; ULSAM ¼ Uppsala Longitudinal Study of Adult Men; WHS ¼ Women’s Health Study; WOSCOPS ¼ West of Scotland
Coronary Prevention Study.
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564We also detected signiﬁcant between-study het-
erogeneity for the associations with the outcomes of
all CVD and fatal CVD. Studies varied in their age
and sex proﬁle, outcome deﬁnitions, follow-up
durations, and degrees of statistical adjustment,
but none of these factors had an inﬂuence on the
strengths of associations observed. However, our
analysis revealed possibly stronger associations in
studies based in North America and with a higher
proportion of nonwhite participants. Although it is
well established that nonwhite participants have
higher cardiac troponin values compared with white
participants (4,7,8,12,15), single studies have so far
not detected that associations of cardiac troponins
with CHD (7) or stroke (8) are modiﬁed according to
ethnicity. Furthermore, we noted a trend toward
stronger associations for hs-cTnT than for hs-cTnI.To shed more light on this preliminary ﬁnding,
future research is needed that evaluates, in a direct
comparison, whether the clinical utility of hs-cTnT
and hs-cTnI measurements depends on the assay
generation or on patient characteristics, including
age, sex, and indicators of myocardial stress.
Although ﬁndings in PROSPER and 3 previous
studies (8,25,26) suggested that the prognostic value
of cardiac troponins does not vary according to
NT-proBNP levels, analysis of large-scale individual-
participant data is required to assess multiplicative
interactions adequately.
BIOLOGICAL MECHANISMS. The traditional view has
been that cardiac troponins are elevated in case of
myocardial necrosis only; however, evidence has
emerged that other heart diseases such as atrial ﬁbril-
lation (43) and cardiac structural and functional
FIGURE 3 Combined Adjusted Relative Risk for CVD Outcomes
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Relative Risk Comparing Top vs. Bottom Third of
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Study-speciﬁc relative risks were pooled by using random effects meta-analysis and compared in the top third versus the bottom third of
cardiac troponin concentration. Abbreviations as in Figure 1.
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565abnormalities (15,44) can also lead tomodest increases
in cardiac troponin concentrations in circulation.
Another relevant factor could be subclinical coronary
atherosclerosis. Coronary angiography studies have
shown close correlations between the severity of
coronary atherosclerosis and cardiac troponin
concentration (45). It is speculated that clinically
silent ruptures of coronary plaques triggerCENTRAL ILLUSTRATION Troponin and Risk
Willeit, P. et al. J Am Coll Cardiol. 2017;70(5):558–68.
In assessing the association of cardiac troponin concentration and CVD
concentration were deﬁned within each study separately. Study-speciﬁc
meta-analysis, demonstrating that high cardiac troponin levels in the no
illustrative and cardiac troponin distributions were not normally distribumicroembolizations and, consequently, the shedding
of troponin from cardiomyocytes via membranous
blebs (46). A third mechanism could be the link be-
tween cardiac troponin concentration and cardiac
stress characterized by activation of the adrenergic and
renin-angiotensin-aldosterone systems. This rela-
tionship has been demonstrated in patients with heart
failure (47).of CVD Outcomes
outcomes, we identiﬁed 28 relevant studies. Thirds of cardiac troponin
relative risks for ﬁrst-ever CVD outcomes were pooled by using a random effects
rmal range are associated with increased CVD event risk. The distribution graph is
ted. CHD ¼ coronary heart disease; CVD ¼ cardiovascular disease.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Meta-analysis of published studies suggests that
people with elevated circulating troponin concentra-
tions in absence of clinically manifest myocardial
injury are at a relatively high risk of developing
cardiovascular events.
TRANSLATIONAL OUTLOOK: Future research is
needed to clarify the predictive value of cardiac
troponin measurements in relation to conventional
cardiovascular risk factors.
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566CLINICAL RELEVANCE. Our data also suggested that
cardiac troponin assessment could be a useful adjunct
to conventional risk factors in predicting CVD risk. In
line with a preferential association of cardiac tropo-
nins with fatal CVD, assessment of hs-cTnT in the
PROSPER study yielded greater improvements for
predicting fatal CVD than overall CVD. For fatal CVD,
it yielded improvements in the C-index as well as
categorical and continuous NRIs. For the overall CVD
outcome, hs-cTnT assessment only improved the
continuous NRI.
Another group of biomarkers that has emerged as a
potential adjunct to CVD risk prediction are the natri-
uretic peptides. In the Natriuretic Peptides Studies
Collaboration, a large collaborative individual-
participant-data meta-analysis, NT-proBNP demon-
strated associations with CVD (RR: 1.76; 95% CI:
1.56 to 1.98) and CHD (RR: 1.67; 95% CI: 1.45 to
1.93) that were of similar magnitude to those
observed in PROSPER for hs-cTnT (48). The associa-
tion between hs-cTnT and CVD risk was weakened
in PROSPER after adjustment for NT-proBNP but
remained signiﬁcant. It might be that a combination
of these biomarkers or a more extensive panel
of complementary biomarkers will provide the great-
est improvement in prediction. However, this
approach might be limited by cost, which requires
further study.
Furthermore, the data presented from PROSPER
and studies in the current meta-analysis all classi-
ﬁed participants on the basis of a single measure-
ment of cardiac troponin. Diurnal variability in
cardiac troponin has been observed with moderately
higher levels during the morning (49), and short-
term variability was present both in those with
and without known coronary artery disease (50).
This biological variation will need to be explored
further to inform selection of appropriate cutoffs for
use in clinical practice. Evaluations of the prog-
nostic value of changes in cardiac troponin over
time have suggested that the trajectory of cardiac
troponin might provide additional prognostic infor-
mation (12,51).
Recent data from the WOSCOPS (West of Scotland
Coronary Prevention Study) trial showed that pra-
vastatin signiﬁcantly lowered hs-cTnI in a manner
consistent with lower CVD risk (28). This recent
paper, along with our summation of available pro-
spective data on troponins and CVD risk, suggests
that more research on troponins as markers of clinical
utility beyond the diagnosis of an acute coronary
syndrome is urgently needed.STUDY LIMITATIONS. This study provided de novo
data from the PROSPER study andwas strengthened by
concurrent reporting of a comprehensive review of the
literature regarding the association between cardiac
troponin and incident CVD. Transformation of study-
speciﬁc HRs to reﬂect RR between those with cardiac
troponin values in the upper third compared with the
lower third allowed a common scale to be used when
pooling studies and has been used in the assessment of
a number of biomarkers (52). It did, however, assume
that the relationship between the biomarker of interest
and disease risk was linear. In the meta-analysis, there
was signiﬁcant between-study heterogeneity that
could have resulted from several differences between
the included studies as discussed earlier. Inherent
limitations exist in the use of study-level data in this
meta-analysis, and the availability of individual-
participant data would allow for further standardiza-
tion of analytical techniques, covariate adjustment,
and subgroup analysis.
CONCLUSIONS
Elevated cardiac troponin concentration, well within
the normal range, was associated with an increased
risk of incident CVD outcomes in the general popu-
lation. This association was strongest for fatal CVD
and persisted after adjustment for conventional
CVD risk factors. Further research on cardiac
troponin as a useful marker of risk prediction seems
warranted.
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